Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xiaowei Chen, Xiaobin Xie & Wei Zhou. (2020) CircCFL1/MiR-107 Axis Targeting HMGB1 Promotes the Malignant Progression of Diffuse Large B-Cell Lymphoma Tumors. Cancer Management and Research 12, pages 9351-9362.
Read now
Read now
Neelam Lohani, Himanshu Narayan Singh, Shweta Agarwal, Ranjana Mehrotra & Moganty R. Rajeswari. (2015) Interaction of adriamycin with a regulatory element of hmgb1: spectroscopic and calorimetric approach. Journal of Biomolecular Structure and Dynamics 33:8, pages 1612-1623.
Read now
Read now
Yasuyuki Inoue, Tasuku Saito, Kohei Ogawa, Yuji Nishio, Shigeki Kosugi, Yoshinori Suzuki, Hirotaka Sakai, Masayuki Kato, Masatomo Takahashi & Ikuo Miura. (2013) Role of serum high mobility group box 1 in hematological malignancies complicated with systemic inflammatory response syndrome and effect of recombinant thrombomodulin. Leukemia & Lymphoma 54:9, pages 1953-1958.
Read now
Read now
Articles from other publishers (26)
Sourour Idoudi, Takwa Bedhiafi, Shona Pedersen, Mohamed Elahtem, Izzaldin Alremawi, Sabah Akhtar, Said Dermime, Maysaloun Merhi & Shahab Uddin. (2023) Role of HMGB1 and its associated signaling pathways in human malignancies. Cellular Signalling 112, pages 110904.
Crossref
Crossref
Caiqin Wang, Yu Wang, Jianghua Cao, Xiaoqing Sun, Xiaohua He, Peng Sun, Tianxiao Gao, Jiajia Huang & Zhiming Li. (2021) Elevated expression of HMGB1 is prognostic of poor survival in patients with relapsed/refractory T/NK-CL. Annals of Hematology 100:9, pages 2293-2302.
Crossref
Crossref
Giuseppe Murdaca, Alessandro Allegra, Francesca Paladin, Fabrizio Calapai, Caterina Musolino & Sebastiano Gangemi. (2021) Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma. International Journal of Molecular Sciences 22:16, pages 9039.
Crossref
Crossref
Rana Muhammad Usman, Faryal Razzaq, Arshia Akbar, Arafat Ali Farooqui, Ahmad Iftikhar, Azka Latif, Hamza Hassan, Jianjun Zhao, Jennifer S. Carew, Steffan T. Nawrocki & Faiz Anwer. (2020) Role and mechanism of autophagy‐regulating factors in tumorigenesis and drug resistance. Asia-Pacific Journal of Clinical Oncology 17:3, pages 193-208.
Crossref
Crossref
Bo Li, Xin Peng, He Li, Fei Chen, Yuxia Chen, Yingqian Zhang & Kai Le. (2020) The performance of the alarmin HMGB1 in pediatric diseases: From lab to clinic. Immunity, Inflammation and Disease 9:1, pages 8-30.
Crossref
Crossref
Nikolaus Handke, Alexander Rupp, Nicolai Trimpop, Joachim von Pawel & Stefan Holdenrieder. (2021) Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients. Diagnostics 11:2, pages 356.
Crossref
Crossref
Shunling Yuan, Zhaoping Liu, Zhenru Xu, Jing Liu & Ji Zhang. (2020) High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Wen Shu. (2018) Downregulation of high mobility group protein box‑1 resensitizes ovarian cancer cells to carboplatin. Oncology Letters.
Crossref
Crossref
Min Jiang, Xuelian Li, Xiaowei Quan, Xiaoying Li & Baosen Zhou. (2018) Single Nucleotide Polymorphisms in HMGB1 Correlate with Lung Cancer Risk in the Northeast Chinese Han Population. Molecules 23:4, pages 832.
Crossref
Crossref
Seidu A. Richard. (2018) High-mobility group box 1 is a promising diagnostic and therapeutic monitoring biomarker in Cancers: A review. AIMS Molecular Science 5:4, pages 183-241.
Crossref
Crossref
Si-Jia He, Jin Cheng, Xiao Feng, Yang Yu, Ling Tian & Qian Huang. (2017) The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget 8:38, pages 64534-64550.
Crossref
Crossref
C Hernandez, P Huebener & R F Schwabe. (2016) Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35:46, pages 5931-5941.
Crossref
Crossref
LI WANG, HUIPING ZHANG, MIN SUN, ZHANGHUA YIN & JIHONG QIAN. (2015) High mobility group box 1-mediated autophagy promotes neuroblastoma cell chemoresistance. Oncology Reports 34:6, pages 2969-2976.
Crossref
Crossref
Mithalesh Kumar Singh, Lata Singh, Neelam Pushker, Seema Sen, Anjana Sharma, Feeroj Ahamad Chauhan & Seema Kashyap. (2015) Correlation of High Mobility Group Box-1 Protein (HMGB1) with Clinicopathological Parameters in Primary Retinoblastoma. Pathology & Oncology Research 21:4, pages 1237-1242.
Crossref
Crossref
Man Ru Bi, Li Ying Zhu, Bing Zhu Yan, Li Yan Chen, Fu Xiang Wang, Ying Ji Ma & Bao Shan Yang. (2014) Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression. Hepatitis Monthly 14:12.
Crossref
Crossref
Banzhou Pan, Dongqin Chen, Jiayuan Huang, Rui Wang, Bing Feng, Haizhu Song & Longbang Chen. (2014) HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Molecular Cancer 13:1.
Crossref
Crossref
Kamolporn Amornsupak, Tonkla Insawang, Peti Thuwajit, Pornchai O-Charoenrat, Suzanne A Eccles & Chanitra Thuwajit. (2014) Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer 14:1.
Crossref
Crossref
Rui Kang, Ruochan Chen, Qiuhong Zhang, Wen Hou, Sha Wu, Lizhi Cao, Jin Huang, Yan Yu, Xue-gong Fan, Zhengwen Yan, Xiaofang Sun, Haichao Wang, Qingde Wang, Allan Tsung, Timothy R. Billiar, Herbert J. ZehIIIIII, Michael T. Lotze & Daolin Tang. (2014) HMGB1 in health and disease. Molecular Aspects of Medicine 40, pages 1-116.
Crossref
Crossref
Shiro Kanegasaki, Kouji Matsushima, Kenshiro Shiraishi, Keiichi Nakagawa & Tomoko Tsuchiya. (2014) Macrophage Inflammatory Protein Derivative ECI301 Enhances the Alarmin-Associated Abscopal Benefits of Tumor Radiotherapy. Cancer Research 74:18, pages 5070-5078.
Crossref
Crossref
Annunziata Gloghini, Chiara C. Volpi, Dario Caccia, Ambra V. Gualeni, Anna M. Cilia, Antonino Carbone & Italia Bongarzone. (2014) Primary Effusion Lymphoma. The American Journal of Pathology 184:3, pages 618-630.
Crossref
Crossref
Emilie DejeanMarianne FoisseauFréderic LagarrigueLaurence LamantNaïs Prade, Abdelghafour Marfak, Georges DelsolSylvie GiuriatoFréderique Gaits-IacovoniFabienne Meggetto. (2012) ALK+ALCLs induce cutaneous, HMGB-1–dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation. Blood 119:20, pages 4698-4707.
Crossref
Crossref
Asami ISHIDA, Koichi OHNO, Kenjiro FUKUSHIMA, Ko NAKASHIMA, Masashi TAKAHASHI, Yuko GOTO-KOSHINO, Yasuhito FUJINO & Hajime TSUJIMOTO. (2011) Plasma High-Mobility Group Box 1 (HMGB1) in Dogs with Various Diseases: Comparison with C-Reactive Protein. Journal of Veterinary Medical Science 73:9, pages 1127-1132.
Crossref
Crossref
Guoqiang Bao, Qing Qiao, Huadong Zhao & Xianli He. (2010) Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World Journal of Surgical Oncology 8:1.
Crossref
Crossref
A. Meyer, N. Eberle, J. Bullerdiek, I. Nolte & D. Simon. (2010) High-mobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy. Veterinary and Comparative Oncology 8:2, pages 127-137.
Crossref
Crossref
Xingjun Yao, Gang Zhao, Hongfa Yang, Xinyu Hong, Li Bie & Guojin Liu. (2009) Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. Journal of Cancer Research and Clinical Oncology 136:5, pages 677-684.
Crossref
Crossref
K. Fujii, Y. Luo, T. Sasahira, A. Denda, H. Ohmori & H. Kuniyasu. (2009) Co-treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells. Cell Proliferation 42:5, pages 701-709.
Crossref
Crossref